



January 13, 2025

Adimab Provides Year-End Update on 2024 Partnership Activities

- 17 New Partnerships -
- 51 Milestones Achieved in 2024 -
- Over 600 Total Therapeutic Programs at Year-End -

Lebanon, New Hampshire – January 13, 2025 - Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 17 new companies in 2024. In addition, Adimab announced the expansion of eight of its current partnerships and the achievement of 51 technical and development milestones across numerous collaborations.

Adimab has partnered with over 130 companies to discover therapeutic programs, to date. New alliances for 2024 include collaborations with Candid Therapeutics, Champlain Bio, GV.M1, Helicore Biopharma, Incendia Therapeutics, Inc., Leyden Labs, Remunix, Sedare Biosciences, Inc., Stipple Bio, Meiji Seika Pharma and Treeline Biosciences, among others. In addition, Adimab expanded its collaborations with eight partners, including Alnylam, Cullinan Therapeutics, GSK, iOmx, Novartis, Santa Ana Bio, and Werewolf.

In 2024, Adimab and its partners initiated discovery on 62 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to over 600. Many partners retain the contractual rights to initiate additional royalty-bearing programs with Adimab in the future.

"Adimab's platform stands out in the field of protein-based therapeutic discovery due to our unique ability to leverage a highly proprietary eukaryotic discovery system and a vast human antibody library in an IgG format, yielding exceptional specificity and developability in our output," said Guy Van Meter, Chief Business Officer of Adimab. "Across more than 600 therapeutic programs to date, no project has ever been discontinued for developability issues, which is an achievement unmatched by any other technology in the field. This reflects the unparalleled robustness and reliability of our platform."

"Our competitive edge extends beyond technology; it lies in the unmatched experience of our team. At Adimab, we foster a culture where every employee is motivated by the success of our partners, which has allowed us to attract and retain some of the best talent in the industry. With the wisdom gained from hundreds and hundreds of therapeutic programs, we bring a level of expertise that ensures success in every new project. This is another reason why Adimab stands as the most successful antibody technology

company in the industry — enabling our partners to bring better therapeutic programs to patients," said Philip T. Chase, Chief Executive Officer of Adimab.

Technologies

Antibody Discovery: Adimab discovers therapeutic antibodies in IgG and VHH formats through our proprietary yeast-based technology. Adimab can utilize its fully human synthetic diversity as well as additional diversities from *in vivo* sources. Antibodies from Adimab have exquisite specificity and are utilized in a variety of modalities, including monoclonal and multispecific formats, CAR-Ts, ADCs, etc.

Engineering: Adimab has developed and refined its engineering capabilities over thousands of lead antibody optimization efforts. The process starts with one or more partner-selected lead antibodies with the goal of optimizing potency, specificity, and/or developability. In addition to Adimab-discovered antibodies, engineered antibodies can originate from outside sources, typically to fix undesirable properties of antibodies from *in vivo* and phage-based technologies. Adimab also applies its engineering expertise to cytokines, TCRs, and other proteins.

Multispecifics: Adimab has extensive bispecific and multispecific know-how and capabilities, including proprietary solutions for both Fc (HC:HC) and Fab (HC:LC) heterodimerization, to allow for the generation of numerous bispecific and multispecific product designs with excellent developability properties. Additionally, Adimab can perform common light chain and fragment-based discovery and engineering necessary for certain partner-desired formats.

T Cell Engagers: Adimab has a highly characterized suite of functional and diverse CD3 (both IgG and VHH binders) and CD28 antibodies to generate bi- and multi-specific T cell engagers. Adimab has partnered this program non-exclusively with more than 25 partners, to date.

Complex Targets: Certain membrane-obligate proteins (e.g., GPCRs and ion channels) are often poorly behaved outside their native membrane environment. For these targets, Adimab has developed proprietary *in vitro* and *in vivo* discovery workflows that rely solely on the target being expressed in its native membrane and without the need for antigen mimetics. The company has employed these workflows numerous times to generate robust panels of functional and specific antibodies to these classically difficult targets, which are then further extensively engineered with our yeast platform.

About Adimab

Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice and humans), antibody engineering and optimization, multispecific antibody engineering, and a portfolio of proprietary CD3 and CD28 antibodies licensed non-exclusively for bispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with over 130 pharmaceutical and biotechnology companies, generating more than 600 therapeutic

programs, over 75 clinical programs, and multiple approved products. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Alnylam, Bristol Myers Squibb, Novartis, Regeneron, Vertex and others. Adimab has also partnered with many early-stage venture-backed companies, including Dragonfly, NextPoint, Santa Ana Bio, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Therapeutics, Innovent, iTeos, Mersana, Scholar Rock, and others.

Adimab's integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

Guy Van Meter
Chief Business Officer
Adimab, LLC
(603) 653-5775
guy.vanmeter@adimab.com